Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310016, China; Key Laboratory of Mechanism Research and Precision Repair of Orthopaedic Trauma and Aging Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310016, China.
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310016, China; Key Laboratory of Mechanism Research and Precision Repair of Orthopaedic Trauma and Aging Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310016, China; Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325088, China.
Free Radic Biol Med. 2024 Sep;222:43-61. doi: 10.1016/j.freeradbiomed.2024.06.002. Epub 2024 Jun 6.
There is a growing interest in using extracellular vesicles (EVs) for therapeutic applications. EVs are composed of cytoplasmic proteins and nucleic acids and an external lipid bilayer containing transmembrane proteins on their surfaces. EVs can alter the state of the target cells by interacting with the receptor ligand of the target cell or by being internalised by the target cell. Blood cells are the primary source of EVs, and 1 μL of plasma contains approximately 1.5 × 10 EVs. Owing to their easy acquisition and the avoidance of cell amplification in vitro, using blood cells as a source of therapeutic EVs has promising clinical application prospects. This review summarises the characteristics and biological functions of EVs derived from different blood cell types (platelets, erythrocytes, and leukocytes) and analyses the prospects and challenges of using them for clinical therapeutic applications. In summary, blood cell-derived EVs can regulate different cell types such as immune cells (macrophages, T cells, and dendritic cells), stem cells, and somatic cells, and play a role in intercellular communication, immune regulation, and cell proliferation. Overall, blood cell-derived EVs have the potential for use in vascular diseases, inflammatory diseases, degenerative diseases, and injuries. To promote the clinical translation of blood cell-derived EVs, researchers need to perform further studies on EVs in terms of scalable and reproducible isolation technology, quality control, safety, stability and storage, regulatory issues, cost-effectiveness, and long-term efficacy.
人们对利用细胞外囊泡(EVs)进行治疗应用越来越感兴趣。EVs 由细胞质蛋白和核酸以及表面含有跨膜蛋白的外部脂质双层组成。EVs 可以通过与靶细胞的受体配体相互作用或被靶细胞内化来改变靶细胞的状态。血细胞是 EVs 的主要来源,1μL 血浆中大约含有 1.5×10EVs。由于其易于获取且避免了体外细胞扩增,因此使用血细胞作为治疗性 EVs 的来源具有很有前景的临床应用前景。本综述总结了不同血细胞类型(血小板、红细胞和白细胞)来源的 EVs 的特征和生物学功能,并分析了它们用于临床治疗应用的前景和挑战。总之,血细胞衍生的 EVs 可以调节不同的细胞类型,如免疫细胞(巨噬细胞、T 细胞和树突状细胞)、干细胞和体细胞,并在细胞间通讯、免疫调节和细胞增殖中发挥作用。总体而言,血细胞衍生的 EVs 有可能用于血管疾病、炎症性疾病、退行性疾病和损伤。为了促进血细胞衍生的 EVs 的临床转化,研究人员需要在可扩展和可重复的分离技术、质量控制、安全性、稳定性和储存、监管问题、成本效益和长期疗效等方面对 EVs 进行进一步研究。